Anchiano Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.16 (-0.53 %)
(As of 04/21/2021 12:00 AM ET)
Today's Range
Now: $30.23
50-Day Range
MA: $21.77
52-Week Range
Now: $30.23
Volume147,970 shs
Average Volume3.15 million shs
Market Capitalization$224.31 million
P/E Ratio201.53
Dividend YieldN/A
Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Anchiano Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ANCN
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$2.01 per share


Net Income$-27,120,000.00


Market Cap$224.31 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


Why Immunovant, Anchiano, OpGen Are Rallying Today
March 8, 2021 |
Anchiano Therapeutics Ltd. ADR
February 6, 2021 |
February 5, 2021 |
Why Anchiano Therapeutics Is Trading Higher Today
December 15, 2020 |
See More Headlines


Overall MarketRank

0.83 out of 5 stars

Medical Sector

1177th out of 2,024 stocks

Pharmaceutical Preparations Industry

527th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Anchiano Therapeutics (NASDAQ:ANCN) Frequently Asked Questions

What stocks does MarketBeat like better than Anchiano Therapeutics?

Wall Street analysts have given Anchiano Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Anchiano Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Anchiano Therapeutics' next earnings date?

Anchiano Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Anchiano Therapeutics

How were Anchiano Therapeutics' earnings last quarter?

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) posted its earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.12.
View Anchiano Therapeutics' earnings history

Who are Anchiano Therapeutics' key executives?

Anchiano Therapeutics' management team includes the following people:
  • Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 55, Pay $352k)
  • Mr. Neil H. Cohen, CEO & Director (Age 58)
  • Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 83)
  • Mr. Andrew Fine, Chief Financial Officer (Age 51)
  • Mr. Avraham Hampel M.B.A., Deputy CFO & Company Sec.
  • Mr. Or Dolev, Controller (Age 43)

Who are some of Anchiano Therapeutics' key competitors?

What other stocks do shareholders of Anchiano Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Abeona Therapeutics (ABEO), Aurora Cannabis (ACB), Achieve Life Sciences (ACHV), Acorda Therapeutics (ACOR), Acasti Pharma (ACST), Aduro Biotech (ADRO) and AnaptysBio (ANAB).

When did Anchiano Therapeutics IPO?

(ANCN) raised $35 million in an initial public offering (IPO) on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Anchiano Therapeutics' stock symbol?

Anchiano Therapeutics trades on the NASDAQ under the ticker symbol "ANCN."

What is Anchiano Therapeutics' stock price today?

One share of ANCN stock can currently be purchased for approximately $30.23.

How much money does Anchiano Therapeutics make?

Anchiano Therapeutics has a market capitalization of $224.31 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Anchiano Therapeutics have?

Anchiano Therapeutics employs 16 workers across the globe.

What is Anchiano Therapeutics' official website?

The official website for Anchiano Therapeutics is

Where are Anchiano Therapeutics' headquarters?

Anchiano Therapeutics is headquartered at ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139.

How can I contact Anchiano Therapeutics?

Anchiano Therapeutics' mailing address is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-4622 or via email at [email protected]

This page was last updated on 4/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.